Immune Thrombocytopenic Purpura – Current treatment – Immune Thrombocytopenic Purpura | Treatment Algorithms: Claims Data Analysis | US | Dashboard
Immune thrombocytopenic purpura (ITP) has a complex treatment algorithm comprising many therapies, different combinations of which serve as first-, second-, and later-line treatments. Key therapeutic classes include corticosteroids, immunomodulators, thrombopoietin receptor agonists (TPO-RAs), and an orally administered Syk inhibitor (Rigel’s Tavalisse), which was approved for ITP in 2018 and offers patients a novel treatment option with a mechanism distinct from TPO-RAs. Developers seeking to better understand where and how effectively novel entrants to the ITP market are incorporated into the treatment algorithm will benefit from the insights offered in this content.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed ITP patients?
- What are the quarterly trends in prescribing among recently treated and newly diagnosed ITP patients?
- How has Tavalisse been integrated into the treatment algorithm, and what is its source of business?
- What percentage of ITP patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of ITP patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The Treatment Algorithms dashboard supplements our claims data analysis report and retains the full set of analyses included in the PowerPoint-based report. The interactive dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.
Steven Trueman, Ph.D., is a principal analyst in the Infectious, Niche, and Rare Diseases team at DRG, part of Clarivate. Since 2015, he has specialized in both product development and the production of high-value market analysis reports, forecasts, and custom client decision and strategy solutions. His expertise spans numerous therapy areas, including antiviral indications, niche and rare markets, and oncology indications for all major pharmaceutical markets, including China. Prior to joining DRG, he received his doctorate in biomedical sciences from the University of Massachusetts Medical School and his B.S. in biochemistry from Worcester Polytechnic Institute.